Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO-BACK: Golimumab Withdrawal in nr-axSpA
NCT03253796Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2017
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 4, randomised, double-blind trial of golimumab in non-radiographic axial spondyloarthritis (nr-axSpA) (4 arms), sponsored by Merck & Co. Primary endpoint: Percentage of Participants Without a Disease Activity Flare During Period 2 at 12 months. Started Nov 2017; status: completed.
02
Drugs
golimumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT03253796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03253796.